ArticleBMC medical imaging2026
Preoperative tumor cerebral blood flow measured by arterial spin labeling predicts enhancing tumor volume progression in gliomas: a single-center retrospective study.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundArterial spin labeling (ASL) enables non-invasive quantification of cerebral blood flow (CBF). The preoperative prognostic value of tumor-specific CBF for subsequent enhancing tumor (ET) volume progression in gliomas remains poorly characterized.
methodsIn this study 60 glioma patients (predominantly glioblastoma, WHO grade 4) with preoperative 3T ASL MRI and paired follow-up structural MRI were analyzed. Tumor CBF, surrounding CBF, and whole-brain CBF were quantified from the segmented regions of interest. ET and surrounding non-enhancing FLAIR-hyperintense (SNFH) volume changes were calculated and correlated with preoperative perfusion data. Spearman correlations, Kruskal-Wallis tests, multivariable linear and logistic regression, and ROC analyses were performed.
resultsHigher preoperative tumor CBF strongly predicted net ET volume increase (Spearman r = 0.531, p < 0.0001) and ET progression category (Kruskal-Wallis p = 0.0005). Mean tumor CBF was 147.7 ml/100 g/min in ET-increased versus 124.4 ml/100 g/min in unchanged and 115.8 ml/100 g/min in decreased cases. Tumor CBF remained an independent predictor after adjusting for age, scan interval, and MGMT status (linear regression p = 0.002; logistic regression OR = 2.02 per ml/100 g/min, p = 0.001). Associations with SNFH volume changes were weak and non-significant. Surrounding CBF closely matched whole-brain CBF (Pearson r ≈ 1.00). Tumor CBF alone yielded 5-fold CV AUC = 0.805 for predicting ET progression; the combined model (tumor CBF + ET volume) improved to AUC = 0.858.
conclusionPreoperative ASL-derived tumor CBF appears to be an independent non-contrast imaging biomarker for early enhancing tumor progression risk in gliomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.